您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Nagilactone B
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nagilactone B
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nagilactone B图片
CAS NO:19891-51-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品名称
竹柏内酯 B
产品介绍
Nagilactone B 是一种肝 X 受体 (LXR) 激动剂。
生物活性

Nagilactone B is aliver X receptor(LXR) agonist.

IC50& Target

LXR[1]

体外研究
(In Vitro)

RAW264.7 cells are co-incubated with oxLDL (20 μg/mL) and Nagilactone B (0.02, 0.1, and 0.5 μM) for 24 h. Oil Red O (ORO) staining reveals significant lipid accumulation and foam cell formation in RAW264.7 cells following oxLDL treatment. Nagilactone B (NLB) significantly ameliorates intracellular lipid accumulation. ORO positive areas are reduced by 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001) in Nagilactone B (0.02, 0.1, and 0.5 μM)-treated groups, respectively. The effects of Nagilactone B are evaluated ton cholesterol efflux. Nagilactone B (0.02, 0.1, and 0.5 μM) markedly promotes cholesterol efflux to extracellular apolipoprotein A-I (apoA-I) and high density lipoprotein (HDL) with maximal 5.72- (P<0.05) and 2.34-fold (P<0.01), respectively[1].

体内研究
(In Vivo)

Nagilactone B (NLB) suppresses atherosclerosis in apoE-/-mice by inducing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) mediated cholesterol efflux in macrophages. Male apoE-deficient mice on C57BL/6J background receive Nagilactone B (10 and 30 mg/kg) for 12 weeks. Compared with the model group, Nagilactone B treatment (10 and 30 mg/kg) significantly reducesen facelesions of total aorta areas. Six-week-old male apoE-/-mice on an HFD are randomized to receive Atorvastatin (10 mg/kg/day), Nagilactone B (10 and 30 mg/kg/day), or CMC-Na for 12 weeks. Mice on chow diet are administered CMC-Na as the normal diet control group.En faceaortic lesion areas are evaluated with Sudan IV staining and lesion areas in the aortic sinus monitored via ORO staining. Atherosclerosis developes slowly in the normal diet group, whereas lesions in the HFD model group are significantly increased inen faceaortas. Nagilactone B treatment (10 and 30 mg/kg/day) significantly reducesen faceaortic lesions, compared with the HFD group by 54.96±10.06% (P<0.01), 71.50±15.37% (P<0.001) in both NLB (L) and NLB (H) groups. In particular, Nagilactone B markedly attenuates atherosclerotic plaque lesion areas in the aortic arch aorta, thoracic aorta, and abdominal aorta [P<0.01 in NLB (H) group][1].

分子量

364.39

性状

Solid

Formula

C19H24O7

CAS 号

19891-51-1

中文名称

竹柏内酯 B

结构分类
  • Terpenoids
  • Other Terpenoids
来源
  • Plants
  • Podocarpaceae
  • Podocarpus nagi
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month